NCT01629966

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 680 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Placebo	Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
DRUG	Vilazodone	Vilazodone, 20mg, oral administration once per day.
DRUG	Vilazodone	Vilazodone, 40mg, oral administration once per day.

Timeline

• Start date: 2012-06-30
• Primary completion: 2014-02-28
• Completion: 2014-03-31
• First posted: 2012-06-28
• Last updated: 2019-12-18
• Results posted: 2019-12-18

Locations

37 sites across 1 country: United States